Does Ozempic cause blindness? Very rarely, it may. In diabetes studies, semaglutide, the drug in Ozempic, added about 1 case of sudden vision loss per 10,000 users a year (Review). That vision loss, called NAION, usually strikes only one eye, so total blindness is rare (Study).
What Is NAION?
NAION is short for non-arteritic anterior ischemic optic neuropathy. The optic nerve is the cable that carries signals from your eye to your brain. In NAION, blood flow to the front of that nerve drops, and part of the nerve is damaged. That is why people sometimes call it an eye stroke.
“Non-arteritic” means it is not caused by inflamed arteries. Inflamed arteries point to a different condition, giant cell arteritis, which doctors need to rule out.
The classic sign is sudden, painless vision loss in one eye. Some people see a dark or blurry patch in part of their view. Many first notice it when they wake up. Because it does not hurt, it is easy to put off getting it checked.
NAION is rare. A long-running study in Olmsted County, Minnesota, counted 104 cases between 1990 and 2016 (Study). That works out to about 4 new cases per 100,000 people a year. In adults aged 50 and over, it was about 10 per 100,000. The typical patient was 65, and the rate had barely moved in four decades. All of these numbers come from before Ozempic reached the market.
Is It Really Twice as Common?
David Sinclair, a longevity scientist, called NAION “like a stroke in your eye” on The Joe Rogan Experience (episode 2537, 2026). He said it is now twice as common because of GLP-1 drugs, the class Ozempic belongs to. The data give the “twice” some support. The “because of” is less certain, and so is what “twice” means for you.
The worry started at one hospital. In 2024, a study in JAMA Ophthalmology looked back at patient records from Massachusetts Eye and Ear in Boston (Study). Among people with type 2 diabetes, about 9 in 100 on semaglutide got NAION within three years. On other diabetes drugs, it was about 2 in 100. In people with overweight or obesity, it was about 7 in 100 on semaglutide. On other weight-loss drugs, it was about 1 in 100.
Those numbers sound alarming, but the patients were not typical: all had already seen eye nerve specialists. The study counted only 17 and 20 cases on semaglutide in its two groups. The authors warned that their results “should be considered with caution for the general population” (Study). They also could not check whether patients took the drugs as prescribed.
Two kinds of risk matter here. Relative risk tells you how much a risk grows compared with where it started. Absolute risk tells you how many people are affected. When the starting risk is tiny, doubling it still leaves it small.
National health registries in Denmark and Norway show why that difference matters (Study). They followed about 61,000 people with type 2 diabetes who started semaglutide: 44,517 in Denmark and 16,860 in Norway. A comparison group started a different type of diabetes drug. There were 32 NAION cases on semaglutide. That is about 2 to 3 cases per 10,000 users a year, against about 1 on the other drug.
After adjusting for differences between the groups, semaglutide added about 1.4 cases per 10,000 people a year. Put another way, about 9,997 of every 10,000 users went a full year without NAION. The authors did find a link. Still, they concluded that “the absolute risk remains low.”
Europe’s drug safety committee reached a similar view in June 2025 (Review). It concluded that NAION is a “very rare” side effect of semaglutide, which means up to 1 in 10,000 people. In adults with diabetes, it put the extra risk at about 1 case per 10,000 people treated for a year. The committee also asked for NAION to be added to the product information.
The UK regulator, the MHRA, followed in February 2026 (Safety update). From 2018 to August 2025, it had received just 3 reports suggestive of NAION. Over the five years to September 2025, about 10.2 million packs were dispensed.
So Sinclair’s “twice” roughly matches the diabetes data. But the extra risk behind it is still only about 1 case per 10,000 users a year.
What the Big Studies Found
Most of the larger studies that came after Boston found a smaller rise. Some found none.
Almost all of them are observational. Researchers looked back at the records of people who chose, with their doctors, to take a drug. Nobody decided by coin flip who got it. So semaglutide users may differ from non-users in ways that also affect their eyes. That problem is called confounding. It can make a drug look riskier, or safer, than it really is.
The biggest study covered 37.1 million adults with type 2 diabetes across 14 health databases (Study). It included 810,390 new semaglutide users. Among them, NAION showed up in about 9 to 15 people per 100,000 a year. The range depends on how strictly NAION was defined. The researchers also compared the same people on and off the drug. The rate was about a third to a half higher while they were on it. The authors called this a “modest increase,” smaller than earlier reports.
That study also turned up a puzzle. When semaglutide went head to head with other diabetes drugs, most gaps were small enough that chance could explain them (Study). Another GLP-1 drug, exenatide, showed a rise on one definition of NAION. So it is not clear the risk belongs to semaglutide alone.
Another large records study found no rise at all (Study). Among people with diabetes on semaglutide, 0.065% had NAION over five years. That is about 6 or 7 people in every 10,000. It was no higher than in matched people on other diabetes drugs. Boston, by contrast, found 9 in 100 over three years.
That study has limits too. It found NAION cases through billing codes rather than eye exams (Study). So it argues against a big jump in risk. It does not show that semaglutide protects the eyes.
A meta-analysis pools the results of many studies into one estimate. Three were published in 2026. All three found more NAION on semaglutide in the observational data.
A review in Ophthalmology split the data by study type and by reason for use (Meta-analysis). In observational studies of people with diabetes, NAION ran at about 27 cases per 100,000 people a year on semaglutide. Without it, the rate was about 19. In 8 trials with 31,174 people, any difference was small enough that chance could explain it. People using semaglutide for weight loss showed no clear rise in either kind of study.
A review in Neurology pooled 5 observational studies with nearly 1.6 million patients (Meta-analysis). It found about two and a half times the risk on semaglutide. The authors rated the evidence as low to moderate certainty. A review in PLOS Medicine found roughly double the risk in type 2 diabetes (Meta-analysis). That works out to about 1 extra case for every 7,000 people treated for a year. Its authors called it a possible link, not a proven cause.
Trials give a murkier answer. In a trial, a coin flip decides who gets the drug, which removes most confounding. A 2025 review of 78 such trials did find more NAION on semaglutide (Meta-analysis). But only 5 of those trials, with 25,330 people, reported NAION at all. The review’s best guess was about 1 extra case per 10,000 people. The authors had low confidence in that figure.
Why can’t trials settle it? Most were not designed to look for eye problems. Nearly half did no eye exams or eye scans (Meta-analysis). And with a condition this rare, there were too few cases for a clear answer. Europe’s regulator read the trial data as pointing to a “slightly higher risk” (Review).
Who Is Most at Risk
Many things raise NAION risk on their own. Several of them, such as diabetes, are also reasons people take semaglutide. That overlap is the confounding problem described above.
In the Minnesota study, about 8 in 10 NAION patients had high blood pressure (Study). About 4 in 10 had diabetes, and nearly 1 in 4 had sleep apnea. Each was more common than in people of the same age without NAION.
A review of 49 studies put rough numbers on each factor taken alone (Meta-analysis). Diabetes raised the risk by about half. High blood pressure raised it by roughly 30%. Sleep apnea roughly tripled it, though the studies disagreed with each other a lot. These were raw figures, not adjusted for each other, and the factors often show up together.
Obstructive sleep apnea stands out. A separate review of 5 studies linked it to roughly six times the chance of NAION (Meta-analysis). That estimate was uncertain, and the authors called for more research. If you snore loudly or wake up tired, read our guide to the signs of sleep apnea.
Anatomy matters too. Some people have a small, crowded optic disc. In a crowded disc, the nerve fibers squeeze through a tight opening at the back of the eye. It is often seen in people with NAION (Meta-analysis). An eye doctor can spot one during a normal eye exam.
A past NAION is the clearest warning sign. In the Minnesota study, about 1 in 5 patients later had NAION in the other eye (Study).
The extra risk shows up mainly in people with diabetes, who carry more of these risk factors. Boston did see a rise in its weight-loss group. Pooled data have not confirmed it so far (Meta-analysis).
Other GLP-1 drugs have far less data. One study lumped semaglutide and tirzepatide (Mounjaro, Zepbound) together (Study). Over two years, 35 of about 80,000 users got NAION. A matched group on other diabetes drugs, some of them older GLP-1s, had 19 cases. Only about 1 in 22 users took tirzepatide alone, too few to judge it.
A second study, in adults with type 2 diabetes, linked tirzepatide to fewer NAION cases than other GLP-1 drugs (Study). Both studies looked back at records, so neither settles it. The UK regulator is still reviewing other GLP-1 drugs (Safety update). Two leading eye groups say not to assume the risk belongs to semaglutide alone (Summary).
Vision Loss? What to Do
Sudden vision loss in one eye is an emergency, whatever drugs you take. See an eye doctor the same day, so other causes can be ruled out quickly. For sudden or fast-worsening vision loss, the UK regulator’s advice is clear. Go urgently to eye casualty or an emergency department (Safety update).
Do not stop semaglutide on your own. Stopping can carry real health risks for some people, such as those with hard-to-control diabetes or heart disease (Summary). Talk to your prescriber first.
The official advice differs by region. In Europe and the UK, regulators say to stop semaglutide if NAION is confirmed (Review). Two North American eye groups take a softer line in a 2026 statement (Consensus statement). They are the North American Neuro-Ophthalmology Society (NANOS) and the American Academy of Ophthalmology. Their statement calls the link possible but unproven, and the overall risk low. It advises patients and their care team to decide together whether to start, continue or stop the drug. That includes after a new NAION diagnosis (Summary).
In the US, the Ozempic prescribing information does not list NAION as of October 2026 (Label). Its only eye warning covers diabetic retinopathy, a separate eye problem linked to diabetes. It does tell patients to report any changes in their vision.
If you have had NAION before, tell your prescriber before you start. The NANOS and Academy statement asks that each decision weigh the person’s own risk factors and overall health (Summary).
If NAION does happen, there is no proven treatment (Review). Some people do regain part of their sight on their own. A US trial of 244 people compared eye surgery with careful follow-up alone (Trial). Within six months, about 4 in 10 people without surgery could read three or more extra lines on the eye chart. Only about 3 in 10 improved that much after surgery, and more surgery patients got worse. The trial concluded that surgery did not work and might do harm.
New treatments are in testing, and one ties back to Sinclair. Life Biosciences, a company he co-founded, began a small safety trial of a gene therapy called ER-100 in 2026 (NCT07290244). It includes people with NAION. Our post on the first human trial of cellular reprogramming explains what that trial can and cannot show.
Frequently Asked Questions
How Rare Is Ozempic Blindness?
Very rare. Europe’s regulator lists NAION as a “very rare” side effect of semaglutide, affecting up to 1 in 10,000 people (Review). In diabetes studies, the drug may add about 1 case per 7,000 to 10,000 users a year (Meta-analysis). Blindness in both eyes is rarer still.
Is Ozempic Blindness Reversible?
Sometimes, in part. In one US trial, about 4 in 10 people with untreated NAION regained some sight within six months (Trial). Those figures come from NAION in general, not drug-linked cases. No treatment has been proven to restore vision (Review).
Can You Go Blind From Ozempic?
Total blindness from Ozempic is very unlikely, because NAION usually affects one eye. The second eye is hit in about 1 in 7 people over five years, more often in people with diabetes (Study). The vision loss in that one eye can still be serious. And it is not yet proven that the drug causes NAION.
Why Does Ozempic Cause Blindness?
Nobody knows, and it is not proven that it does. One idea is that the drug lowers blood pressure, which could reduce blood flow to the optic nerve. Researchers offer this only as a possibility (Study). Confounding may also play a part. Many people on semaglutide have diabetes, high blood pressure or sleep apnea. Each of these raises NAION risk on its own (Meta-analysis).
Key Takeaways
- The absolute risk is tiny: Semaglutide may add about 1 NAION case per 10,000 users a year. Europe calls it “very rare” (Review).
- Double a rare risk is still rare: In Danish and Norwegian registries, 32 of about 61,000 users got NAION. That is about 1.4 extra cases per 10,000 a year (Study).
- Real-world records and trials differ: The rise shows up in records of people with diabetes. Trials have too few cases to settle it, and weight-loss use shows no clear rise so far (Meta-analysis).
- Some people should take extra care: Diabetes, sleep apnea and high blood pressure each raise NAION risk on their own (Meta-analysis). A past NAION is the clearest warning sign (Study).
- Act fast, but do not stop alone: Sudden vision loss means a same-day eye exam. Decide about the drug with your care team (Consensus statement).
Weigh the Risk, Watch Your Eyes
For many people, semaglutide brings big gains in blood sugar control and weight. The eye risk looks real but small, so weigh the two together with your prescriber. Bring it up especially if you have had NAION, have sleep apnea or have a crowded optic disc.
Remember the one warning sign: sudden, painless vision loss in one eye. If it happens, see an eye doctor that day. Call your prescriber before you change anything.
The evidence on Ozempic and NAION is still building, and so far the absolute risk is small.
This article is for educational purposes and is not medical advice. Talk to a qualified clinician before changing your health regimen.
Leave a Reply